Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Open-Label, Multicenter, Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and Sotigalimab in Patients With Metastatic Pancreatic Cancer

NCT05419479 is registered in ClinicalTrials.gov with James Cleary, MD, PhD as lead sponsor.

NCT NCT05419479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05419479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Open-Label, Multicenter, Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and Sotigalimab in Patients With Metastatic Pancreatic Cancer
Lead sponsor
James Cleary, MD, PhD
Phase
Phase 1/2
Overall status
Suspended
Start date
November 30, 2022
Completion date
May 17, 2032
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, adenosquamous carcinoma of the pancreas, pancreatic cancer, squamous cell carcinoma of pancreas